Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Market Cap	43.62B
Revenue (ttm)	7.03B
Net Income (ttm)	431.14M
Shares Out	n/a
EPS (ttm)	0.50
PE Ratio	101.17
Forward PE	n/a
Dividend	0.62 (2.04%)
Ex-Dividend Date	Jun 7, 2024

Volume	2,252,128
Average Volume	3,977,625
Open	29.50
Previous Close	30.25
Day's Range	29.40 - 30.80
52-Week Range	25.05 - 58.80
Beta	0.94
RSI	39.31
Earnings Date	Mar 28, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 9,701
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3347

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY